PATENT CLAIM ANALYSIS

Application Number: 16281790
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["424", "009100"]

Abstract:
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Claim (Index 1):
A method of treating a patient who has cancer, comprising administering to said patient a composition comprising a population of activated T cells that kill the cancer cells in the patient that aberrantly express a peptide, wherein said peptide consists of the amino acid sequence selected from the group consisting of SEQ ID NO: 408, SEQ ID NO: 519, from SEQ ID NO: 1 to SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 10, from SEQ ID NO: 12 to SEQ ID NO: 56, from SEQ ID NO: 58 to SEQ ID NO: 147, from SEQ ID NO: 149 to SEQ ID NO: 197, from SEQ ID NO: 199 to SEQ ID NO: 265, from SEQ ID NO: 267 to SEQ ID NO: 407, from SEQ ID NO: 409 to SEQ ID NO: 426, and from SEQ ID NO: 428 to SEQ ID NO: 465, from SEQ ID NO: 467 to SEQ ID NO: 511, from SEQ ID NO: 513 to SEQ ID NO: 518, from SEQ ID NO: 520 to SEQ ID NO: 586, and from SEQ ID NO: 588 to SEQ ID NO: 663, wherein said cancer is selected from the group consisting of ovarian cancer, non-small cell lung cancer, small cell lung cancer, kidney cancer, brain cancer, colon or rectum cancer, stomach cancer, liver cancer, pancreatic cancer, prostate cancer, leukemia, breast cancer, Merkel cell carcinoma, melanoma, esophageal cancer, urinary bladder cancer, uterine cancer, gallbladder cancer, and bile duct cancer.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 99.0
- Lexical Diversity: 1.61972
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['16101081', '15980328', '15199182', '15199066', '15198853']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8808271952917761
- 35 USC 102 Novelty (BERT): 0.6468833954752802
- Combined Prediction Score: 0.8574328153101266
- Mean Citation Score: 790.308978
- Max Citation Score: 794.89325
- Similarity Product: 578.1704827294201

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test